NEUK203-13

N/A

Report date: 2026/02/20 20:02:00

Base Information

Drug NameNEUK203-13

Drug Alias NameNEUK203-13

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cells modulatorsAnti-Delta-like protein 3

TargetsDelta-like protein 3

Therapy Area/IndicationsSmall Cell Lung CarcinomaNeuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesNeukio Biotherapeutics (Shanghai) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesNeukio Biotherapeutics (Shanghai) Co Ltd

Inactive CompaniesN/A

Active IndicationsSmall Cell Lung CarcinomaNeuroendocrine Tumors

Inactive IndicationsN/A

Other Information

ATC CodeN/A